Vivos Therapeutics, Inc. (NASDAQ:VVOS) Stock Short Interest Climbs 76.1%

Vivos Therapeutics, Inc. (NASDAQ:VVOS) saw a significant increase in short interest in September. As of September 30th, there was short interest totaling 2,864,201 shares, an increase of 76.1% from the September 15th total of 1,626,351 shares. Currently, 21.1% of the company’s stock are short sold. Based on an average daily volume of 8,031,092 shares, the days-to-cover ratio is currently 0.4 days.

Vivos Therapeutics Stock Up 5.2%

Shares of VVOS traded up $0.01 during mid-day trading on Thursday, reaching $0.14. 3,352,905 shares of the stock traded hands, compared to its average volume of 4,719,366. The firm has a market cap of $1.96 million, a price-to-earnings ratio of -0.07 and a beta of 6.11. The stock has a fifty day simple moving average of $0.20 and a 200 day simple moving average of $0.52. Vivos Therapeutics has a 12-month low of $0.13 and a 12-month high of $3.21.

Vivos Therapeutics (NASDAQ:VVOS) last posted its earnings results on Friday, August 14th. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.10. The business had revenue of $5.15 million for the quarter, compared to analysts’ expectations of $5.63 million. Vivos Therapeutics had a negative net margin of 122.00% and a negative return on equity of 2,325.64%. On average, equities research analysts expect that Vivos Therapeutics will post -1.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $2.80.

Institutional Investors Weigh In On Vivos Therapeutics

An institutional investor recently bought a new stake in Vivos Therapeutics stock. Sequoia Financial Advisors LLC bought a new position in shares of Vivos Therapeutics, Inc. (NASDAQ:VVOS) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 24,000 shares of the company’s stock, valued at approximately $28,000. Sequoia Financial Advisors LLC owned about 0.18% of Vivos Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 26.35% of the company’s stock.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on developing and commercializing non-surgical treatments for sleep-related breathing disorders and related craniofacial conditions. The company’s primary focus is obstructive sleep apnea, a disorder in which the upper airway repeatedly narrows or becomes blocked during sleep.

The company markets the Vivos System, a series of customized oral appliances designed to help reposition and support the upper airway. Its offerings include the Vivos Complete Airway Repositioning Appliance (CARE) and other dental devices intended to improve airway function during sleep.